John P. Perentesis MD, FAAP

John P. Perentesis MD, FAAP
Professor/ Division DirectorCollege of Medicine--UCJohn.Perentesis@cchmc.org
CHRF-2372 Mail Location 7015 3333 Burnet Avenue Cincinnati OH 45229
Phone:513-636-6090Fax: 513-636-3549
  • Experimental Therapeutics
  • Pediatric Oncology (Developing)

Research Description

Dr. Perentesis' clinical research focuses on the development of molecularly targeted therapies for pediatric and adolescent cancer. His laboratory program focuses on complementary studies of leukemia biology and pharmacogenetics of childhood cancer therapy. The laboratory has developed novel recombinant anticancer drugs, and discovery of genes involved in cellular regulation. Dr. Perentesis is also committed to expansion of the zebrafish model system in oncology.

Current Publications

  • Blaney SMA phase I trial of MK-2206 in children with refractory malignancies: A children's oncology group study.Pediatr Blood Cancer 3/24/2014
  • Balis FMPhase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.Neuro Oncol 2/4/2014
  • Horan JDifferences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.Cancer 119 4162-9 12/1/2013
  • Cooper TM, Razzouk BI, Gerbing R, Alonzo TA, Adlard K, Raetz E, Gamis AS, Perentesis JP, Whitlock JAPhase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): a report from the Children's Oncology Group.Pediatr Blood Cancer 60(7) 1141-7 7/1/2013
  • Perentesis JChildren's Oncology Group's 2013 blueprint for research: adolescent and young adult oncology.Pediatr Blood Cancer 60(6) 6/1/2013
  • Gamis AS, Alonzo TA, Perentesis JP, Meshinchi SChildren's Oncology Group's 2013 blueprint for research: acute myeloid leukemia.Pediatr Blood Cancer 60(6) 964-71 6/1/2013
  • Phillips CL, Davies SM, McMasters R, Absalon M, O'Brien M, Mo J, Broun R, Moscow JA, Smolarek T, Garzon R, Blum W, Schwind S, Marcucci G, Perentesis JPLow dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults.Br J Haematol 161(3) 406-10 5/1/2013
  • Busaidy NL, Farooki A, Dowlati A, Perentesis JP, Dancey JE, Doyle LA, Brell JM, Siu LLManagement of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway.J Clin Oncol 30(23) 2919-28 8/10/2012
  • Chang KH, Sanchez-Aguilera A, Shen S, Sengupta A, Madhu MN, Ficker AM, Dunn SK, Kuenzi AM, Arnett JL, Santho RA, Agirre X, Perentesis JP, Deininger MW, Zheng Y, Bustelo XR, Williams DA, Cancelas JAVav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival.Blood 120(4) 800-11 7/26/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu